Halozyme Therapeutics, Inc. (FRA:RV7)
Germany · Delayed Price · Currency is EUR | Market Cap | 10.63B +48.4% |
| Revenue (ttm) | 1.46B +41.2% |
| Net Income | 362.02M -25.8% |
| EPS | 2.96 -22.5% |
| Shares Out | n/a |
| PE Ratio | 29.37 |
| Forward PE | 10.72 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 93.26 |
| Previous Close | 92.84 |
| Day's Range | 93.26 - 93.26 |
| 52-Week Range | 52.50 - 93.36 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Halozyme Therapeutics
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) admini... [Read more]
Financial Performance
In 2025, Halozyme Therapeutics's revenue was $1.40 billion, an increase of 37.55% compared to the previous year's $1.02 billion. Earnings were $316.89 million, a decrease of -28.64%.
Financial numbers in USD Financial StatementsNews
Halozyme Appoints Dannielle Appelhans to its Board of Directors
SAN DIEGO, Aug. 18, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans brings mor...
Halozyme price target raised to $95 from $75 at Wells Fargo
Wells Fargo raised the firm’s price target on Halozyme (HALO) to $95 from $75 and keeps an Equal Weight rating on the shares. The firm cites a Q2 beat/raise driven…
Halozyme price target raised to $105 from $93 at Morgan Stanley
Morgan Stanley analyst Sean Laaman raised the firm’s price target on Halozyme (HALO) to $105 from $93 and keeps an Overweight rating on the shares.
Halozyme price target raised to $105 from $96 at TD Cowen
TD Cowen raised the firm’s price target on Halozyme (HALO) to $105 from $96 and keeps a Buy rating on the shares. The firm updated its model following strong Q2…
Halozyme price target raised to $95 from $75 at Wells Fargo
Wells Fargo raised the firm’s price target on Halozyme (HALO) to $95 from $75 and keeps an Equal Weight rating on the shares. The firm notes Q2 beat/raise was driven…
Leerink upgraded Halozyme to Outperform on growth, market leadership
As previously reported, Leerink upgraded Halozyme (HALO) to Outperform from Market Perform with a price target of $110, up from $83. The firm expects additional upside to consensus revenue and…
Halozyme upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Halozyme (HALO) to Outperform from Market Perform with a price target of $110, up from $83.
Halozyme price target raised to $93 from $92 at Citizens
Citizens raised the firm’s price target on Halozyme (HALO) to $93 from $92 and keeps an Outperform rating on the shares. Halozyme delivered a strong Q2 with better-than-expected results driven…
Halozyme price target raised to $115 from $95 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Halozyme (HALO) to $115 from $95 and keeps a Buy rating on the shares. The company reported “another royalty-led beat and raise”…
Halozyme Therapeutics Earnings Call Transcript: Q2 2026
Record Q2 results featured 48% revenue growth, driven by robust ENHANZE royalties and new deals. Guidance for 2026 was raised, with strong momentum from both established and newly launched products, and significant expansion into ADC and nucleic acid modalities.
Halozyme Therapeutics Earnings release: Q2 2026
Halozyme Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Halozyme Therapeutics Quarterly report: Q2 2026
Halozyme Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Halozyme Therapeutics Slides: Q2 2026
Halozyme Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
Total Revenue Increased 48% YOY to $481 million Royalty Revenue Increased 50% YOY to $308 million Raises 2026 Financial Guidance Ranges: Total Revenue of $1.835 - $1.910 billion, YOY Growth of 31% - 3...
Halozyme to Report Second Quarter 2026 Financial and Operating Results
SAN DIEGO, July 23, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its second quarter 2026 financial and operating results on Thursday, Au...
Halozyme's Partnerships, Earnings Growth See Shares Near All-Time Highs
Halozyme Therapeutics, Inc. (HALO) shares gain 539% since first Big Money outlier inflow signal in March 2014.
Halozyme announces global collaboration, license agreement with Incyte
Halozyme Therapeutics (HALO) announced that it has entered into a global collaboration and license agreement with Incyte (INCY) to evaluate additional subcutaneous formulations of INCA033989, a first-...
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two additional targets SAN DIEGO, July 20, 2026 /PRNewsw...
Halozyme Appoints David Ramsay as President Drug Delivery
SAN DIEGO, June 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug Delivery, effective ...
LifeMD partners with Halozyme subsidiary for exclusive testosterone program
LifeMD (LFMD) announced a strategic co-marketing collaboration with Antares Pharma, a subsidiary of Halozyme (HALO), supporting a direct-to-patient self-pay program for Xyosted. Under the agreement, L...
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
SAN DIEGO, June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based ...
Halozyme price target lowered to $93 from $96 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Halozyme (HALO) to $93 from $96 and keeps an Overweight rating on the shares. Halozyme reported “solid” Q1 results, 2026-2028 guidance was…
Halozyme Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw 42% revenue and 43% royalty growth, driven by ENHANZE-enabled products and strong partner launches. Guidance for 2026–28 was reaffirmed, with new collaborations, a $1B buyback, and robust pipeline momentum supporting long-term growth.
Halozyme Therapeutics Earnings release: Q1 2026
Halozyme Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.